Bristol-Myers Squibb plans to shutter the San Diego, US, site following last year’s merger

Bristol-Myers Squibb (BMS) has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin.

Since BMS bought Amylin last year, around 100 jobs have already been eliminated at the San Diego site. In an email to FierceBiotech, a BMS spokesman confirmed that the company aims to have all operations transferred to other BMS sites by the end of 2014, and the site completely closed early in 2015. 100–125 employees will be offered relocation packages to other BMS sites, with the rest of the 420 staff being made redundant.